Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection.

Trial Profile

Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs ATX-GD 59 (Primary)
  • Indications Graves' disease
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 03 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 24 Jan 2017 Planned number of patients changed from 30 to 15.
    • 10 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top